Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Accumulated Expenses (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Other Accumulated Expenses data on record, last reported at $7.9 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 1247.86% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $7.9 million, up 1247.86%, while the annual FY2025 figure was $7.9 million, 1247.86% up from the prior year.
  • Other Accumulated Expenses reached $7.9 million in Q4 2025 per RVMD's latest filing, down from $8.2 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $8.2 million in Q3 2025 and bottomed at $104000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $1.8 million, with a median of $492500.0 recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 85.04% in 2024, then surged 1247.86% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $311000.0 in 2021, then surged by 62.38% to $505000.0 in 2022, then surged by 671.49% to $3.9 million in 2023, then tumbled by 85.04% to $583000.0 in 2024, then soared by 1247.86% to $7.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $7.9 million in Q4 2025, $8.2 million in Q3 2025, and $462000.0 in Q2 2025.